anti-CD19/BCMA CAR-T cells
/ Hrain Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 06, 2021
Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R POMES
(clinicaltrials.gov)
- P1; N=10; Active, not recruiting; Sponsor: Hrain Biotechnology Co., Ltd.; Recruiting ➔ Active, not recruiting
Enrollment closed • Multiple Myeloma
1 to 1
Of
1
Go to page
1